Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations

Obstetrics and Gynecology

Volumn 96, Issue 3, 2000, Pages 366-372

  Symons, James ^a,b   Kempfert, Nona ^b   Speroff, Leon ^b,c  

^a FemHRT STUDY INVESTIGATORS   (United States)

^b PFIZER INC   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; NORETHISTERONE ACETATE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPOTTING; VAGINA BLEEDING;

ADULT; AGED; CLIMACTERIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ETHINYL ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NORETHINDRONE; RISK; UTERINE HEMORRHAGE;

EID: 0034734975     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006250-200009000-00009     Document Type: Article

References (34)

1. Coope J, Thomson JM, Poller I. Effects of natural oestrogen replacement therapy on menopausal symptoms and blood clotting. BMJ 1975/4:139-43.
2. Strickler RC, Borth R, Cecutti A, Cookson BA, Harper JA, Potvin R, et al. The role of oestrogen replacement in the climacteric syndrome. Psychol Med 1977;7:631-9.
3. Hovik P, Sundsbak HP, Gaasmyr M, Sandvik L. Comparison of continuous and sequential oestrogen-progestogen treatment in women with climacteric symptoms. Maturitas 19S9;ll:75-82.
4. Casper RF, Chapdelaine A. Estrogen and interrupted progestin: A new concept for menopausal hormone replacement therapy. Am J Obstet Gynecol 1993;168:1188-96.
5. Erlik Y, Meldrum DR, Judd HL. Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol 1982;59:403-7.
6. Hagan C, Christiansen C, Christensen MS, Transbol I. Climacteric symptoms, fat mass, and plasma concentrations of LH, FSH, Prl, 17-oestradiol and androstenedione in the early post-menopausal period. Acta Endocrinol 1982;101:87-92.
7. Mango D, Scirpa P, Battaglia F, Bini E. Plasma androstenedione and oestrone levels in the climacteric syndrome. Maturitas 1984;5: 245-50.
8. Christiansen C. Hormonal prevention and treatment of osteoporosis-state of the art 1990. J Steroid Biochem Mol Biol 1990;37:447-9.
9. Ettinger B, Genant H, Conn CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102:319-24.
10. Ross RK, Paganini-Hill A, Mack JM, Arthur M, Henderson BE. Menopausal estrogen therapy and protection from death from ischémie heart disease. Lancet 1981;i:858-62.
11. Stampfer MJ, Graham A, Colditz MB, Wille WC, Manson JE, Rosner B, et al. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;352:756-62.
12. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
13. Whitcroft SIJ, Stevenson JC. Hormone replacement therapy: Risks and benefits. Clin Endocrinol (Oxf) 1992;36:15-20.
14. Barrett-Connor E. Risks and benefits of replacement estrogen. Annu Rev Med 1992;43:239-51.
15. Lobo RA. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 1995;173:982-90.
16. Nachtigall LE. Enhancing patient compliance with hormonal replacement therapy at menopause. Obstet Gynecol 1990;75:577-80.
17. Keil D, Felson D, Anderson J, Wilson P, Moskowitz M. Hip fracture and the use of estrogen in postmenopausal women-the Framingham Study. N Engl J Med 1987;317:1169-74.
18. Berman RS. Patient compliance of women taking estrogen replacement therapy. Drug Inf J 1997;31:71-83.
19. Berman RS, Epstein RS, Lydick E. Risk factors associated with women's compliance with estrogen replacement therapy. J Wornens Health 1997;6:219-26.
20. Hammon CB. Women's concerns with hormone replacement therapy-compliance issues. Fertil Steril 1994;62(suppl 2):157S-60S.
21. Staland B. Continuous treatment with natural oestrogens and progestogens: A method to avoid endometrial stimulation. Maturitas 1981;3:145-56.
22. Magos AL, Brincat M, Studd JWW, Wardle P, Schlesinger P, O'Dowd T, et al. Amenorrhea and endometrial atrophy with continuous oral oestrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1985;65:496-9.
23. Sporrong T, Hellgren M, Samsioe G, Mattison L. Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints. Br J Obstet Gynaecol 1988;95: 1042-8.
24. Marsh MS, Whitehead MI. The practicalities of hormone replacement therapy. Baillieres Clin Endocrinol Metab 1993;7:183-202.
25. Doren M, Schneider HPG. The impact of different HRT regimens on compliance. Int J Fertil 1996;41(suppl 1):362-71.
26. Weinstein L, Bewtra C, Gallagher C. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990;162:1534-42.
27. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994;83:686-92.
28. Hillard TC, Siddle NC, Whitehead MI, Fräser DI, Pryse-Davies J. Continuous combined conjugated equine estrogen-progestogen therapy: Effects of medroxyprogesterone acetate and norethin-drone acetate on bleeding patterns and endometrial histologie diagnosis. Am J Obstet Gynecol 1992;167:l-7.
29. Hillard TC, VVhitcroft SI, Marsh MS, Ellerington MC, Lees B, Whitehead MI, et al. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos Int 1994;4:341-8.
30. Marsleu' U, Overgaard K, Riis BJ, Christiansen C. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: Long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet Gynecol 1992;79:202-10.
31. Doren M, Reuther G, Minne HW, Schneider HPG. Superior compliance and efficacy of continuous combined oral estrogenprogestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol 1995;173:1446-51.
32. Luciano AA, DeSouza MI, Roy MP, Schoenfeld MJ, Nulsen JC, Halvarson CV. Evaluation of low-dose estrogen and progestin therapy in postmenopausal women. J Reprod Med 1993;38:207-14.
33. Andersson K, Mattsson LA, Rybo C, Stadberg E. Intrauterine release of levonorgestrel-a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992;79:963-7.
34. Speroff L, Rowan J, Symons J, Genant H, Wilbom W. The compar-ative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study): A randomized controlled trial. JAMA 1966;276:1397-403.